RU2014132426A - Частичные конструкты мнс и способы их применения - Google Patents

Частичные конструкты мнс и способы их применения Download PDF

Info

Publication number
RU2014132426A
RU2014132426A RU2014132426A RU2014132426A RU2014132426A RU 2014132426 A RU2014132426 A RU 2014132426A RU 2014132426 A RU2014132426 A RU 2014132426A RU 2014132426 A RU2014132426 A RU 2014132426A RU 2014132426 A RU2014132426 A RU 2014132426A
Authority
RU
Russia
Prior art keywords
domain
polypeptide
mhc class
activity
peptide antigen
Prior art date
Application number
RU2014132426A
Other languages
English (en)
Russian (ru)
Inventor
Артур А. ВАНДЕНБАРК
Грегори Г. БАРРОУЗ
Роберто МЕЗА-РОМЕРО
Джил БЕНЕДЕК
Шейн ЭНДРЮ
Джеффри МУНИ
Original Assignee
Орегон Хэлт Энд Сайенс Юниверсити
Дзе Юнайтед Стэйтс Гавернмент Эз Репрезентед Бай Дзе Дипартмент Оф Ветеранс Афэрс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Орегон Хэлт Энд Сайенс Юниверсити, Дзе Юнайтед Стэйтс Гавернмент Эз Репрезентед Бай Дзе Дипартмент Оф Ветеранс Афэрс filed Critical Орегон Хэлт Энд Сайенс Юниверсити
Publication of RU2014132426A publication Critical patent/RU2014132426A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
RU2014132426A 2012-01-06 2013-01-04 Частичные конструкты мнс и способы их применения RU2014132426A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584045P 2012-01-06 2012-01-06
US61/584,045 2012-01-06
PCT/US2013/020287 WO2013103816A1 (en) 2012-01-06 2013-01-04 Partial mhc constructs and methods of use

Publications (1)

Publication Number Publication Date
RU2014132426A true RU2014132426A (ru) 2016-02-27

Family

ID=47561855

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014132426A RU2014132426A (ru) 2012-01-06 2013-01-04 Частичные конструкты мнс и способы их применения

Country Status (11)

Country Link
US (1) US20150044245A1 (enExample)
EP (1) EP2800582A1 (enExample)
JP (1) JP6364352B2 (enExample)
KR (1) KR20140114859A (enExample)
CN (1) CN104105503A (enExample)
AU (1) AU2013207489A1 (enExample)
BR (1) BR112014016652A2 (enExample)
CA (1) CA2860678A1 (enExample)
MX (1) MX2014008146A (enExample)
RU (1) RU2014132426A (enExample)
WO (1) WO2013103816A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2242393C1 (ru) * 2003-05-12 2004-12-20 Производственное республиканское унитарное предприятие "Минский автомобильный завод" Механизм опрокидывания кабины
US8685404B2 (en) * 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
US10316075B2 (en) 2013-10-03 2019-06-11 Oregon Health & Science University Recombinant polypeptides comprising MHC class II α1 domains
US20150099706A1 (en) * 2013-10-03 2015-04-09 Oregon Health & Science University TREATMENT OF ISCHEMIC STROKE WITH DRa1-MOG-35-55
US10525101B2 (en) 2015-10-23 2020-01-07 Oregon Health & Science University Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor
US20170196957A1 (en) 2016-01-08 2017-07-13 Oregon Health & Science University Recombinant t cell receptor ligand compositions and methods for treatment of prostate cancer
US20190248867A1 (en) * 2016-07-01 2019-08-15 Loma Linda University Myelin oligodendrocyte glycoprotein-specific peptide for the treatment or prevention of multiple sclerosis
EP3837271A4 (en) * 2018-08-14 2022-06-15 Board of Regents, The University of Texas System SINGLE MOLECULE SEQUENCING PEPTIDES BOUND TO THE MAIN HISTOCOMPATIBILITY COMPLEX
KR20210071019A (ko) 2018-10-05 2021-06-15 오레곤 헬스 앤드 사이언스 유니버시티 변형된 MHC 클래스 II DRα1 도메인을 포함하는 재조합 폴리펩타이드 및 이의 사용 방법
WO2021113297A1 (en) * 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
DE102020109447A1 (de) * 2020-04-03 2021-10-07 Jacobs University Bremen Ggmbh Synthetisches mhc-klasse-ii-protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
JP3603374B2 (ja) * 1995-04-14 2004-12-22 東レ株式会社 融合蛋白質およびその融合蛋白質を固定化した材料
DE69730038T2 (de) * 1996-08-16 2004-11-25 The President And Fellows Of Harvard College, Cambridge Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
AU741130B2 (en) 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US20030007978A1 (en) 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
BR9908082A (pt) * 1998-02-19 2000-10-31 Harvard College Proteìna de fusão do complexo de histocompatibilidade principal classe ii, conjugado dos domìnios de ligação do complexo de histocompatibilidade principal multimérico, processos para detectar células t tendo uma especificidade do complexo definido de mhc / peptìdeo, para conferir a um indivìduo imunidade adotiva a um complexo definido de mhc / peptìdeo, para estimular ou ativar as células t reativas a um complexo definido de mhc / peptìdeo, para seletivamente matar células t reativas a um complexo definido de mhc / peptìdeo, para tolerizar um indivìduo humano a um complexo definido de mhc / peptìdeo, e, ácido nucleico isolado
EP2783699A1 (en) * 2003-09-05 2014-10-01 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
US7576183B2 (en) * 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
EP1877440A4 (en) 2005-03-18 2009-07-29 Univ Oregon Health & Science RECOMBINANT MHC MOLECULES SUITABLE FOR MANIPULATING ANTIGEN-SPECIFIC T CELLS
US8491913B2 (en) 2009-03-07 2013-07-23 Oregon Health & Science University Compositions and methods using recombinant MHC molecules for the treatment of stroke
US20110008382A1 (en) 2009-03-07 2011-01-13 Burrows Gregory G Compositions and methods using recombinant MHC molecules for the treatment of uveitis

Also Published As

Publication number Publication date
WO2013103816A8 (en) 2014-06-26
AU2013207489A8 (en) 2014-09-18
KR20140114859A (ko) 2014-09-29
CN104105503A (zh) 2014-10-15
CA2860678A1 (en) 2013-07-11
AU2013207489A1 (en) 2014-08-28
JP6364352B2 (ja) 2018-07-25
JP2015505315A (ja) 2015-02-19
EP2800582A1 (en) 2014-11-12
MX2014008146A (es) 2016-02-03
BR112014016652A2 (pt) 2019-09-24
US20150044245A1 (en) 2015-02-12
WO2013103816A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
RU2014132426A (ru) Частичные конструкты мнс и способы их применения
JP2015505315A5 (enExample)
Wiend et al. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials
JP6882782B2 (ja) 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
CN102959082B (zh) 用于治疗自身免疫性和变应性疾病的新组合物和方法
CA2813494A1 (en) Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
WO2013160865A1 (en) Immunotolerizing fusion proteins for treatment of multiple sclerosis
CN115942950A (zh) 治疗炎症性疾病的方法和药物组合物
Leadbetter et al. Experimental autoimmune encephalomyelitis induced with a combination of myelin basic protein and myelin oligodendrocyte glycoprotein is ameliorated by administration of a single myelin basic protein peptide
US20230091257A1 (en) Pocket Engineering of HLA Alleles for Treating Autoimmunity
Falk et al. Induction and suppression of an autoimmune disease by oligomerized T cell epitopes: enhanced in vivo potency of encephalitogenic peptides
Boppana et al. Immunologic aspects of multiple sclerosis
JP7406620B2 (ja) 関節炎治療のためのｈｌａ－ｄｒ／ｃｉｉペプチド複合体
WO2007143174A2 (en) Combination therapy method and formulation
Consonni et al. a novel approach to reinstating Tolerance in experimental autoimmune Myasthenia gravis Using a Targeted Fusion Protein, mcTa1–T146
EP3268382A1 (en) Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use
CN110139659B (zh) 用于治疗干燥综合征的肽
Roufosse et al. Systemic sclerosis (scleroderma)
Culibrk et al. The Role of Chronic Inflammatory Bone and Joint Disorders in the Pathogenesis and Progression of
WO2023183556A2 (en) Treatment for retinal disorders
JP2016117700A (ja) 制御性ｔ細胞分化誘導剤
STEWART et al. A vaccine-like administration of PLP-PEG-B7AP and MOG-PEG-B7AP
Tsay et al. Targeting the IL-10 Pathway by RNA Interference Has Beneficial Effects on the Development of Experimental Lupus
Davidson The immunobiology of antisecretory factor
Rynda Low dose tolerance vaccine platform, reovirus protein sigma 1 and treatment of autoimmunity

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180208